Targeting tau phosphorylation sites through small molecules or gene editing techniques (DeVos et al., 2017; Yang and Qiu, 2024) holds therapeutic promise in tau-related neurodegenerative diseases, such as AD and frontotemporal dementia. The gene discussed is MAPT; the disease is frontotemporal dementia.